WEHI New Medicines and Diagnostics special seminar hosted by Dr Michael Ricca

Associate Professor Mohammad Haskali, PhD, CRPSS, MRACI CCHEM


Chief Radiopharmaceutical Scientist 


Department of Radiopharmaceutical Sciences, Cancer Imaging

Sir Peter MacCallum Department of Oncology

The University of Melbourne

Integrated Radiopharmaceutical Development Platform: From Target Discovery to Clinical Translation in a Clinical Cancer Center Setting

L7W Seminar Room | Bundoora Large Boardroom

Join via TEAMS

Including Q&A session

Peter Mac’s Integrated Radiopharmaceutical Sciences (iRPS) program operates a comprehensive theranostic development platform spanning the full translational pipeline from target discovery through to clinical application. The department has established end-to-end capability encompassing peptide discovery using innovative approaches including mRNA display, constrained peptide libraries, automated synthesis and large-scale purification, and clinical-grade radiolabelling with diagnostic and therapeutic radionuclides including 18F, ⁶⁸Ga, 89Zr, 64Cu, ¹⁷⁷Lu, ¹⁶¹Tb, ²²⁵Ac, and ²¹²Pb. The program has delivered several first-in-human studies, including [⁶⁸Ga]Ga-DPI-4452 for clear cell renal cell carcinoma and [¹⁶¹Tb]Tb-PSMA-I&T for metastatic castration-resistant prostate cancer, alongside an active radiotracer supply program serving nine researchers across five institutions. With a strong foundation in chemistry, pharmacology, and biology, and a growing portfolio of novel candidates across multiple tumour streams, iRPS is positioned to continue advancing the next generation of targeted radiopharmaceuticals from bench to bedside.

A/Prof Mohammad Haskali holds a PhD in Radiopharmaceutical Sciences from the University of Melbourne and is Peter Mac’s inaugural Chief Radiopharmaceutical Scientist. Following early career roles at Cyclotek Pty. Ltd. and the National Institute of Mental Health (NIMH), USA, he joined Peter MacCallum Cancer Centre in 2016 where he leads both the clinical provision of radiopharmaceuticals and an internationally recognised research program in targeted radionuclide theranostics. He operates the world’s largest therapeutic radiopharmaceutical production facility within a hospital setting, and has overseen the clinical translation of over 5 new radiopharmaceuticals in the past five years. His work has attracted over AUD $20 million in grant funding, resulted in five patents, and produced publications in high-impact journals. He is certified by the Australasian College of Physical Scientists and Engineers in Medicine (ACPSEM), serves as a Director on the ACPSEM College Board, and leads Australia’s national radiopharmaceutical sciences training program under the auspices of the College.

All welcome!